Related Articles
Atacicept Shows Promise in Lupus Treatment Trials
A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease. Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the…
Phase 2 Results for Mavrilimumab Are In
Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA. Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating…
Late-Breaking Abstract Session Spans the Realm of Drug-Related Research
In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.
Drug Updates
Information on New Approvals and Medication Safety